Standard BioTools Inc. (LAB)

Standard BioTools Inc. (LAB) is a healthcare company (medical devices) based in the United States. The share price is $0.62, down 0.97% on the day, which values the company at $242.8M. Price as of 17 Nov 2026, 17:26 UTC, from Yahoo Finance.

Key facts

Share price
$0.62−0.97% today
Market value
$242.8M
Funk Score
23/100
Against its own history
Well below its usual priceusual price $1.10
200-week average
$1.6663% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Standard BioTools Inc. in more detail

LAB trades at -61.5× next year's expected earnings, 2.9× sales. Measured against its own history, the price is 44% below what its usual multiples would imply ($1.10) — well below its usual price. It sits 63% below its 200-week average of $1.66.

Over the last five fiscal years Standard BioTools Inc. has compounded revenue -9.2% a year. Its Funk Score is 23 out of 100 (financial strength 3.6, profitability 0.0, growth 0.7, value 5.0, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Share count keeps rising.

1 of the superinvestors tracked here hold LAB, including Andreas Halvorsen (0.1% of the portfolio).

Superinvestors holding LAB

1 of the investors tracked here report a position in their latest 13F filing.

Standard BioTools Inc. (LAB): questions and answers

What is Standard BioTools Inc.'s market cap?

Standard BioTools Inc. is valued at $242.8M at a share price of $0.62.

Is LAB overvalued or undervalued?

Against its own history, LAB is well below its usual price: the price is 44% below the $1.10 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is LAB above its 200-week moving average?

No. LAB is 62.9% below its 200-week average of $1.66. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Standard BioTools Inc. growing?

Over the last five fiscal years Standard BioTools Inc.'s revenue grew -9.2% a year; over ten years revenue grew -2.9% a year.

Does LAB pay a dividend?

Standard BioTools Inc. does not currently pay a regular dividend.

Which famous investors own LAB?

In their latest quarterly filings, Andreas Halvorsen (0.1% of the portfolio) hold LAB. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Standard BioTools Inc. (LAB) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/LAB

Underlying data: Yahoo Finance; company filings with the SEC.